Integrilin (eptifibatide)
- Region
- 🇪🇺 EU
- Active substance
- eptifibatide
- Company
- GlaxoSmithKline Trading Services Limited
- Status
- Withdrawn
- Therapeutic area
- Angina, Unstable; Myocardial Infarction
- CHMP opinion
- Fri 02 Jul 1999
- EU approval
- Thu 01 Jul 1999
- Application
- EMEA/H/C/000230
- ATC
- B01AC16
- Official record
- www.ema.europa.eu
Indication
Integrilin is intended for use with acetylsalicylic acid and unfractionated heparin. Integrilin is indicated for the prevention of early myocardial infarction in patients presenting with unstable angina or non-Q-wave myocardial infarction with the last episode of chest pain occurring within 24 hours and with ECG changes and / or elevated cardiac enzymes. Patients most likely to benefit from Integrilin treatment are those at high risk of developing myocardial infarction within the first 3-4 days after onset of acute angina symptoms including for instance those that are likely to undergo an early percutaneous transluminal coronary angioplasty (PTCA).
Regulatory milestones
Integrilin: medicine discontinued
Solution for injection, Solution for infusion; Alternatives available: Yes · source
Same substance in other markets
- 🇪🇺 Eptifibatide Accord Authorised · Accord Healthcare S.L.U.
Follow Integrilin
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.